PPT-Gender differences in pre-clinical models of Chemotherapy Induced Neuropathy

Author : naomi | Published Date : 2023-11-22

Daniel W Cohn September 2022 From preclinical to clinical Lack of robust nonevoked pain endpoints Lack of translatable Biomarkers Lack of studies taking gender differences

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Gender differences in pre-clinical model..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Gender differences in pre-clinical models of Chemotherapy Induced Neuropathy: Transcript


Daniel W Cohn September 2022 From preclinical to clinical Lack of robust nonevoked pain endpoints Lack of translatable Biomarkers Lack of studies taking gender differences into account In vivo preclinical. Language and Gender. J.K. Chambers in his textbook on sociolinguistic theory (1995:102) states that “in virtually all sociolinguistic studies that include a sample of males and females” there is clear evidence that “women use fewer stigmatized and non-standardized variants than do men of the same social group in the same circumstances.”. David S. Ettinger, MD. Alex Grass Professor of Oncology. Sidney Kimmel Comprehensive Cancer Center. . at . Johns Hopkins. Disclosure of Conflicts of Interest. David S. Ettinger, MD, discloses that he has served as an advisor/consultant for Gilead, Roche/Genentech, Boehringer Ingelheim, Biodesix, Lilly, and Helsinn Therapeutics.. Week 12. Today’s questions. Why are some people “naturally” happy or sad, angry or calm, anxious or chill, jealous or secure, …?. Why do the same event lead to different emotions? . Why do the same events lead to different intensities . . Do you have . numbness, tingling, burning . sensations in your feet and/or hands?. Our free seminar answers your questions about. Peripheral Neuropathy and what you can do . about. it . to GET YOUR LIFE BACK.. Program Goals. The Importance of Controlling Nausea and Vomiting in the Setting of Chemotherapy. CINV: Consequences. Emetogenicity of IV Chemotherapy. Emetogenicity of Oral Chemotherapy. Types of CINV. Kathleen Brandfass, MS PT . Director of Neuro,Vestibular and Geriatric Outpatient Services. UPMC/Centers for Rehab Services . Objectives. 1. Review Case presentation of Chemo Induced Peripheral Neuropathy (CIPN). November . 10, 2009. Erick Gong. Thanks . to Null . & . Miguel . Agenda. Class Scheduling. Diff-in-Diff (Math & Graphs). Case Study. STATA Help. Class Scheduling. Nov 10: Diff-in-Diff. Nov 17: Power Calculations & Guest Speaker. PDI Medical. What is Neuropathy?. Acquired Neuropathy Causes. Symptoms/Subtypes. Mainstream Treatments. Pain Relievers. OTC medications. Opioids. Anti-seizure medications. gabapentin (. Neurotin. ). pregabalin (Lyrica). 1characteristic pattern of numbness is one in which the distal portions of the nerves are first affected the socalled stockingglovepattern This pattern occurs because nerve fibers are affected accord VAHID SALEHIFAR MD. NEUROLOGIST. FARABI HOSPITAL. Anatomy. Introduction. Common neurological problems. Disordered function and structure of motor, sensory, and autonomic nerves. Causes are . disparate,presentations. Head, Palliative Care Research. Division of Cancer Prevention. NCI: Programmatic Overview of CIPN Portfolio. . March. , 2017. Objectives. Provide an overview of the NCI Community Oncology Research Program (NCORP). Shahid. . Beheshti. University of Medical Science. Semiology. of . neuropathyies. 1-Motor symptoms & signs:. Weakness:distal. muscles (occasionally :. proximal+distal,such. as . GBS,Diabet,CIDP. March 23, 2017. Jennifer Gewandter, PhD, MPH. Presentation objectives. Outline the design challenges and issues to consider when designing a CIPN study during chemotherapy. Summarize how published RCTs have addressed these design challenges. over 55 years of neuropathic toxicity: . if not now, when do we take . aaacttion. . Joanna M . Brell. , MD. Clinical Associate Professor of medicine. Case Western Reserve University. Associate Director Cancer Center for clinical research.

Download Document

Here is the link to download the presentation.
"Gender differences in pre-clinical models of Chemotherapy Induced Neuropathy"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents